Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences (Nasdaq: CTKB) reported second quarter 2026 revenue of $48.1 million, up 6% year over year, driven by instrument growth in the U.S. and China and higher service revenue. GAAP gross profit rose 19% to $28.3 million, with gross margin improving to 59% (53% excluding a one-time tariff refund). Non-GAAP adjusted gross margin was 61% (56% excluding the refund).
Total recurring revenue reached $18.5 million, and on a trailing 12‑month basis represented 35% of total revenue, up from 32% a year earlier. The installed base expanded to 3,933 instruments, adding 142 units in the quarter. Operating expenses rose 15% to $39.7 million, including higher R&D, sales and marketing, and a 24% increase in G&A tied to litigation-related expenses, severance and personnel costs. Net loss widened to $12.2 million, or $0.09 per share, versus $5.6 million a year ago, and adjusted EBITDA shifted to a $1.5 million loss.
Cash, cash equivalents and marketable securities totaled $262.0 million at June 30, 2026. Cytek launched the Cytek Borealis 7‑laser full spectrum flow cytometer and new Cytek Aurora Evo configurations. The company updated 2026 revenue guidance to $207–$212 million, raising the midpoint by $1 million, assuming unchanged foreign exchange rates.
Cytek Biosciences (Nasdaq: CTKB) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a webcast conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments and outlook, accessible via the Investors section of its website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) has opened a new innovation center in Bellevue, Washington, relocating its prior Seattle-area operations to a dedicated facility focused on research and development, customer engagement, and technical training. The company is the sole tenant and has consolidated key functions under one roof.
The Bellevue site includes R&D laboratories, instrument service training and customer demonstration areas, and assembly and testing operations. According to Cytek, the center is a strategic infrastructure investment intended to foster collaboration, accelerate product development, and support solutions for evolving needs in research and clinical applications, including high-dimensional cell analysis.
Cytek Biosciences (Nasdaq: CTKB) will participate in Singular Research’s Las Vegas Invitational Conference, held June 14-16, 2026. Cytek management is scheduled to present on Monday, June 15, 2026, at 11:00 a.m. Pacific Time.
A live and archived webcast will be available on the company’s investor website.
Cytek Biosciences (Nasdaq: CTKB) will showcase major spectral flow cytometry innovations at CYTO 2026 in West Palm Beach, June 6–10, 2026. Highlights include the first public debut of the 7-laser Cytek Borealis system and new automation‑ready Cytek Aurora Evo configurations.
Cytek Biosciences (Nasdaq: CTKB) reported Q1 2026 revenue of $44.1 million, up 6% year-over-year, and service revenue of $15.4 million, up 15% year-over-year. GAAP gross profit was $21.3 million with a 48% gross margin. Net loss was $18.9 million.
Recurring revenue was $18.4 million for the quarter and represented 35% of trailing-12-month revenue. Operating expenses rose 13% and the company reaffirmed full-year 2026 revenue guidance of $205M–$212M. Cash and marketable securities totaled $262.2 million as of March 31, 2026.
Cytek Biosciences (Nasdaq: CTKB) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook.
Live audio will be available in the Investors section of the company website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) marks one year of operations at its 8,500-square-foot Singapore facility on March 9, 2026. The site expanded regional manufacturing capacity, reduced delivery times in key APAC markets, added a dedicated service and training center, and strengthened global supply chain resilience while partnering with local research institutes.
Cytek Biosciences (Nasdaq: CTKB) reported Q4 2025 revenue of $62.1M (+8% YoY) and full-year 2025 revenue of $201.5M (+1% YoY). Recurring revenue grew 21% and comprised 34% of 2025 revenue. GAAP gross margin fell to 52% for 2025; adjusted EBITDA was $5.0M for the year. Net loss was $66.5M, reflecting a $33.1M non-cash valuation allowance on deferred tax assets. Installed base reached 3,664 instruments with 630 placements in 2025. Cytek initiated 2026 revenue guidance of $205M–$212M (2%–5% growth).
Cytek Biosciences (Nasdaq: CTKB) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026. Management will take part in a hybrid presentation and fireside chat at 8:10 a.m. PT / 11:10 a.m. ET.
According to the company, a live and archived webcast will be available via the Investors section at investors.cytekbio.com.